Agenus (AGEN) announced the appointment of Jose Iglesias as chief medical affairs officer, effective November 10. Iglesias will lead global medical affairs for botensilimab and balstilimab as the combination advances through Phase 3 evaluation and becomes available in selected countries through early-access mechanisms, including France’s Autorisation d’Acces Compassionnel program.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AGEN:
- Agenus Inc. Reports Q3 2025 Financial and Clinical Progress
- Promising Developments and Strategic Partnerships Justify Buy Rating for Agenus
- Agenus reports Q3 EPS $1.94, consensus $2.20
- AGEN Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- Agenus Inc. Advances Cancer Treatment with Promising Study Update